Positive Immune-regulators During Chronic Viral Infections
慢性病毒感染期间的积极免疫调节剂
基本信息
- 批准号:10463620
- 负责人:
- 金额:$ 55.92万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-02-01 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:AntibodiesAntibody ResponseAntibody-mediated protectionAntigensAntiviral ResponseAttenuatedAutomobile DrivingB-LymphocytesBacteriaBiological ModelsBiological Response ModifiersBiologyCD4 Positive T LymphocytesCD8-Positive T-LymphocytesCell SurvivalCellsCessation of lifeChronicClostridiumDataDevelopmentDistalDocosahexaenoic AcidsElementsEnvironmentExhibitsFarmGoalsHIVHepatitis B VirusHepatitis CHepatitis C virusHost DefenseHumanImmuneImmune System DiseasesImmune responseImmunityInfectionInterleukin-6KnowledgeLaboratoriesLaboratory miceLymphocytic choriomeningitis virusMusPathway interactionsPhylogenetic AnalysisProductionRegulationReportingResearchRodentRoleSerumSiteSmall IntestinesSpecificityT cell differentiationT cell responseT-LymphocyteTestingThe Jackson LaboratoryTherapeuticTimeViralVirusVirus Diseasesbaseburden of illnesschronic infectioncytokineexhaustionfightinghost microbiotaimmunoregulationin vivointerleukin-21metabolomicsmicrobiomemicrobiotamouse modelnonhuman primatepathogenpreventprogenitorprogrammed cell death protein 1programsreceptor
项目摘要
ABSTRACT
Immune stimulatory pathways are dysregulated during chronic viral infections, preventing timely T cell
and antibody mediated immunity. Human persistent viruses, including human immunodeficiency virus (HIV),
hepatitis C and B viruses (HCV and HBV) cause tremendous disease burden worldwide but are restricted to
human and nonhuman primates, which in turn poses great limitations for experimental-based research.
Importantly, lymphocytic choriomeningitis virus (LCMV) in its natural rodent host has been successfully used
as a model system to uncover common principles underlying the regulation of immune responses during
persistent viral infections, often highlighting basic mechanisms that were later extended into humans.
We have found that interleukin-6 (IL-6) and IL-27 are essential for optimal CD4 T cell differentiation and CD4 T
cell survival, respectively, while they redundantly induce IL-21, a critical factor for CD8 T cell and antibody
responses, late after infection. Consistently, both IL-6 and IL-27 were absolutely required to control chronic
(but not acute) LCMV infection. More recent data indicate that late IL-27 derived from B cells is crucial for viral
control and it is regulated by host microbiota during chronic LCMV infection. The overall goal of the current
proposal is to fully dissect the mechanisms underlying the antiviral effects of B-cell-derived IL-27 as
well as its regulation by host microbiota and related metabolites during persistent infection. To
accomplish this goal, we propose three specific aims. In Aim 1 we will investigate the relationship between
B-cell-derived IL-27 and antiviral responses during chronic LCMV infection. We will test the hypothesis
that B cell-derived-IL-27 is both a dependent and a driver of CD4 T cell responses during chronic infection, and
indirectly enhances antibodies and CD8 T cells, promoting viral control late after infection. In Aim 2 we will
identify the microbiome commensals that enhance IL-27 production by B cells and the impact for
antiviral responses and viral control during chronic LCMV infection. We will investigate the possibility that
Segmented Filamentous Bacteria (SFB), a commensal that associates with accelerated viral control, enhances
IL-27 production by B cells in small intestine as well as T cell responses both locally and at distal sites,
overriding the need for IL-6. Finally, in Aim 3 we will identify microbiota-related metabolites that
modulate IL-27 production by B cells and the impact for antiviral responses and viral control during
chronic LCMV infection. We will investigate the metabolites that associate with the microbiota driving IL-27
production by B cells and evaluate their effects on IL-27 expression (in mouse and human B cells) as well as T
cell responses and viral control in LCMV chronically infected mice.
The knowledge gained from this study will not only enhance our understanding of the basic biology of
key immune regulators (i.e. IL-27, microbiome and related metabolites) but may also be valuable for
therapeutically manipulating these factors during infections and perhaps other immune diseases.
抽象的
慢性病毒感染期间免疫刺激途径失调,阻碍 T 细胞及时发挥作用
和抗体介导的免疫。人类持久性病毒,包括人类免疫缺陷病毒(HIV)、
丙型肝炎病毒和乙型肝炎病毒(HCV 和 HBV)在全世界造成巨大的疾病负担,但仅限于
人类和非人类灵长类动物,这反过来又给基于实验的研究带来了很大的限制。
重要的是,淋巴细胞脉络膜脑膜炎病毒(LCMV)在其天然啮齿动物宿主中已被成功使用
作为模型系统来揭示免疫反应调节的共同原理
持续的病毒感染,通常强调后来扩展到人类的基本机制。
我们发现白细胞介素 6 (IL-6) 和 IL-27 对于最佳 CD4 T 细胞分化和 CD4 T 细胞至关重要
细胞存活,同时它们过度诱导 IL-21,这是 CD8 T 细胞和抗体的关键因素
感染后晚期的反应。一致地,IL-6 和 IL-27 都是控制慢性疾病所必需的。
(但非急性)LCMV 感染。最近的数据表明,源自 B 细胞的晚期 IL-27 对于病毒至关重要
在慢性 LCMV 感染期间,它受到宿主微生物群的调节。当前的总体目标
建议全面剖析 B 细胞来源的 IL-27 抗病毒作用的机制:
以及持续感染过程中宿主微生物群和相关代谢物的调节。到
为实现这一目标,我们提出三个具体目标。在目标 1 中,我们将研究之间的关系
慢性 LCMV 感染期间 B 细胞衍生的 IL-27 和抗病毒反应。我们将检验假设
B 细胞衍生的 IL-27 在慢性感染期间既是 CD4 T 细胞反应的依赖性又是驱动因素,并且
间接增强抗体和 CD8 T 细胞,促进感染后期的病毒控制。在目标 2 中,我们将
确定增强 B 细胞产生 IL-27 的微生物组共生体及其影响
慢性 LCMV 感染期间的抗病毒反应和病毒控制。我们将调查以下可能性
分段丝状细菌 (SFB) 是一种与加速病毒控制相关的共生菌,可增强
小肠中 B 细胞产生 IL-27 以及局部和远端部位的 T 细胞反应,
超越对 IL-6 的需要。最后,在目标 3 中,我们将识别微生物相关的代谢物
调节 B 细胞产生 IL-27 及其对抗病毒反应和病毒控制的影响
慢性 LCMV 感染。我们将研究与驱动 IL-27 的微生物群相关的代谢物
B 细胞的产生并评估其对 IL-27 表达(在小鼠和人类 B 细胞中)以及 T 细胞的影响
LCMV 慢性感染小鼠的细胞反应和病毒控制。
从这项研究中获得的知识不仅将增强我们对基础生物学的理解
关键的免疫调节剂(即 IL-27、微生物组和相关代谢物),但也可能对
在感染和其他免疫疾病期间治疗性地操纵这些因素。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Elina I Zuniga其他文献
Elina I Zuniga的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Elina I Zuniga', 18)}}的其他基金
Molecular Mechanisms Underlying Dendritic Cell Adaptations During Chronic Infection
慢性感染期间树突状细胞适应的分子机制
- 批准号:
10308448 - 财政年份:2019
- 资助金额:
$ 55.92万 - 项目类别:
Molecular Mechanisms Underlying Dendritic Cell Adaptations During Chronic Infection
慢性感染期间树突状细胞适应的分子机制
- 批准号:
10531563 - 财政年份:2019
- 资助金额:
$ 55.92万 - 项目类别:
Molecular Mechanisms Underlying Dendritic Cell Adaptations During Chronic Infection
慢性感染期间树突状细胞适应的分子机制
- 批准号:
9916335 - 财政年份:2019
- 资助金额:
$ 55.92万 - 项目类别:
Positive Immune-regulators During Chronic Viral Infections
慢性病毒感染期间的积极免疫调节剂
- 批准号:
10665609 - 财政年份:2015
- 资助金额:
$ 55.92万 - 项目类别:
Positive Immune-regulators During Chronic Viral Infections
慢性病毒感染期间的积极免疫调节剂
- 批准号:
10223166 - 财政年份:2015
- 资助金额:
$ 55.92万 - 项目类别:
Positive Immune-regulators During Chronic Viral Infections
慢性病毒感染期间的积极免疫调节剂
- 批准号:
8889036 - 财政年份:2015
- 资助金额:
$ 55.92万 - 项目类别:
Positive Immune-regulators During Chronic Viral Infections
慢性病毒感染期间的积极免疫调节剂
- 批准号:
9000617 - 财政年份:2015
- 资助金额:
$ 55.92万 - 项目类别:
GP130 Signaling During Chronic Virus Infection
慢性病毒感染期间的 GP130 信号传导
- 批准号:
8496709 - 财政年份:2012
- 资助金额:
$ 55.92万 - 项目类别:
相似海外基金
Characterizing the SARS-CoV-2 antibody response and associations with patient factors: Serological profiling of participants enrolled in the GENCOV study
描述 SARS-CoV-2 抗体反应及其与患者因素的关联:参与 GENCOV 研究的参与者的血清学分析
- 批准号:
495256 - 财政年份:2023
- 资助金额:
$ 55.92万 - 项目类别:
Understanding the human antibody response to a malaria transmission-blocking vaccine
了解人类抗体对疟疾传播阻断疫苗的反应
- 批准号:
MR/X009491/1 - 财政年份:2023
- 资助金额:
$ 55.92万 - 项目类别:
Research Grant
Probing the role of peptidoglycan modification in the antibody response to Staphylococcus aureus
探讨肽聚糖修饰在金黄色葡萄球菌抗体反应中的作用
- 批准号:
10549646 - 财政年份:2023
- 资助金额:
$ 55.92万 - 项目类别:
Identification of the antigenic targets of the clonal antibody response to Clostridioides difficile infection
鉴定针对艰难梭菌感染的克隆抗体反应的抗原靶点
- 批准号:
10742376 - 财政年份:2023
- 资助金额:
$ 55.92万 - 项目类别:
Genetic, structural and functional profiling of the human antibody response to arenavirus infection
人类抗体对沙粒病毒感染反应的遗传、结构和功能分析
- 批准号:
10688292 - 财政年份:2022
- 资助金额:
$ 55.92万 - 项目类别:
Molecular dissection of IgA antibody response by developing monoclonal IgA antibodies from nasal mucosa of mice
通过从小鼠鼻粘膜中开发单克隆 IgA 抗体对 IgA 抗体反应进行分子剖析
- 批准号:
22H02875 - 财政年份:2022
- 资助金额:
$ 55.92万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mapping the antibody response to Trypanosoma brucei variant surface glycoprotein
绘制布氏锥虫变异表面糖蛋白的抗体反应
- 批准号:
10634694 - 财政年份:2022
- 资助金额:
$ 55.92万 - 项目类别:
Genetic, structural and functional profiling of the human antibody response to arenavirus infection
人类抗体对沙粒病毒感染反应的遗传、结构和功能分析
- 批准号:
10514498 - 财政年份:2022
- 资助金额:
$ 55.92万 - 项目类别:
Factors related to antibody response of COVID-19 vaccines: with focusing on metabolomics
与 COVID-19 疫苗抗体反应相关的因素:重点关注代谢组学
- 批准号:
22H03334 - 财政年份:2022
- 资助金额:
$ 55.92万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mapping the antibody response to Trypanosoma brucei variant surface glycoprotein
绘制布氏锥虫变异表面糖蛋白的抗体反应
- 批准号:
10527979 - 财政年份:2022
- 资助金额:
$ 55.92万 - 项目类别: